Status In progress
Process CDF Review
ID number 1577

Provisional Schedule

Committee meeting 06 February 2020
Expected publication 22 April 2020

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool


Companies sponsors Astra Zeneca (Osimertinib)
Others Department of Health
  NHS England
  NHS Hounslow CCG
  NHS Heywood, Middleton and Rochdale CCG
  Welsh Government
Patient carer groups Black Health Agency
  British Lung Foundation
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie Cancer Care
  Muslim Council of Britain
  Roy Castle Lung Cancer Foundation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  UK Lung Cancer Coalition
Professional groups Association of Cancer Physicians
  Association of Respiratory Nurse Specialists
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  National Lung Cancer Forum for Nurses
  Primary Care Respiratory Society UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society


Associated guideline groups National Collaborating Centre for Cancer
Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord healthcare (docetaxel)
  Allergan (docetaxel)
  Boehringer ingelheim (nintedanib)
  Dr Reddy’s (docetaxel)
  medac GmbH (docetaxel)
  Sanofi (docetaxel)
General commentators Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
Relevant research groups Cochrane Lung Cancer Group
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
27 June 2019 In progress, The Cancer Drugs Fund guidance review of TA416 Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer has now been rescheduled with the new appraisal dates updated on the webpage. In the meantime, new and existing patients will continue to be able to access this treatment under the terms of the managed access arrangement.
25 June 2019 Suspended, NICE are undertaking a Cancer Drugs Fund guidance review of TA416 Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer which recommended the use of osimertinib in the Cancer Drugs Fund while further data were collected. The aim of the review is to decide whether or not the drug can be recommended for routine use after data collection is complete. Following an update from the company about the availability of its analyses, we have suspended this appraisal. Therefore, the appraisal committee meeting will now be rescheduled. Once a date has been confirmed, the website will be updated accordingly.
23 May 2019 Invitation to participate
10 May 2019 In progress, Referred 08 December 2015

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance